Skip to main content

Ortho Clinical, Thermo Fisher Ink Assay Distribution Deal

NEW YORK (360Dx) – Ortho Clinical Diagnostics announced today that it has signed an international distribution and copromotion agreement covering 14 assays with Thermo Fisher Scientific.

Under the terms of the deal, the companies will deliver assays for monitoring therapeutics, immunosuppressants, and drugs of abuse to hospitals, hospital networks, and labs that use Ortho's Vitros 4600 chemistry system and Vitros 5600 integrated system. The assays will initially be launched in North America, Europe, Africa, and the Middle East.

Additional terms were not disclosed.

According to Ortho, the partnership is part of its ongoing MicroTip Partnership Assays (MPA) program, which was established to validate third-party assays for use on its Vitros systems. In October, Ortho signed an MPA agreement with EKF Diagnostic.

"Ortho is committed to its robust internal R&D programs, as well as collaborating with other innovative companies to expand its menu and bring greater medical value to our customers," Ortho COO Robert Yates said in a statement.